Skip to main content
OpenTrials

Clinical trial condition

HIV-1 Infection

Explore clinical trials studying HIV-1 Infection. Study availability and eligibility vary by location and protocol.

182 public trials 1 recruiting study
Refine in advanced search Browse all conditions

HIV-1 Infection trial results

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935

Conditions
HIV-1 Infection
Locations
  • CHU Saint-Pierre Brussels, Belgium
  • UZ Gent Ghent, Belgium
  • Hopital Saint-Andre Bordeaux, France
  • Hopital Europeen Marseille Marseille, France
View all 25 locations
View Trial Details
Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

NCT02600819

Conditions
Chronic Disease, Disease Attributes, Female Urogenital Diseases, +11 more
Locations
  • Peter J Ruane MD Inc Los Angeles, California, United States
  • University of California Davis Sacramento, California, United States
  • Midway Immunology & Research Center, LLC Ft. Pierce, Florida, United States
  • Infectious Disease Consultants, M.D., P.A. d/b/a Orlando Immunology Center Orlando, Florida, United States
View all 26 locations
View Trial Details
Completed

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

NCT02057796

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +5 more
Locations
  • Sihanouk Hospital Center of Hope Phnom Penh, Cambodia
  • CePReF Centre de Prise en charge de Recherche et de Formation Abidjan, Yopougon, Côte d’Ivoire
  • ISS ImmunoSuppression Service Mbarara, Uganda
  • Pham Ngoc Thach Hospital Ho Chi Minh City, Vietnam
View Trial Details
Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029

Conditions
HIV-1 Infection
Locations
  • Midway Immunology & Research Center, LLC Ft. Pierce, Florida, United States
  • Orlando Immunology Center Orlando, Florida, United States
  • Triple O Research Institute PA West Palm Beach, Florida, United States
  • Hopital Sainte Marguerite - Hospital Marseille, France
View all 21 locations
View Trial Details
Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795

Conditions
HIV-1 Infection
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Spectrum Medical Group Phoenix, Arizona, United States
  • Pacific Oaks Medical Group Beverly Hills, California, United States
  • Kaiser Permanente Hayward, California, United States
View all 78 locations
View Trial Details

Related conditions